Dizal Pharmaceutical is a research-based biotechnology joint venture company between AstraZeneca and Advanced Manufacturing Industry Investment Fund (FIIF) managed by private equity firm China Sate Development & Investment Corporation, dedicated to the discovery, development and commercialization of first-in-class/best-in-class medicines. Since its inception in October 2017, Dizal has worked closely with WuXi STA on CMC for an innovative drug.  

Under the terms of the collaboration, WuXi STA will have exclusive access to BioLingus technology for sublingual and buccal delivery in the contract development and manufacturing organization (CDMO) sector. BioLingus has developed a novel platform – with patents secured in major countries around the world – to stabilize and deliver sublingually (orally under the tongue) drug targets including small molecules, peptides and proteins, that are currently administered to patients via injection.

La donación se realizará el 14 de junio, Día Internacional del Donante de Sangre, en el Museo Arqueológico de Alicante (MARQ)  Las principales instituciones alicantinas respaldan la iniciativa, que pretende superar las 350 donaciones  El chef Pepe Rodríguez colabora ha colaborado en la iniciativa con el diseño del bocadillo que recibirán los donantes

El sector de la medicina encuentra nuevas formas de contacto con los pacientes